Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Recruiting · Phase 1, Phase 2 · NCT04643002
Conditions: Plasma Cell Myeloma Refractory
At a glance
- Research payments reported, 2025
- $156,235
- U.S. investigators named
- 5
- Sites paid
- 4
- Planned or actual enrollment
- 258
About the trial
- Sponsor
- Sanofi
- Tested
- Isatuximab (drug), Dexamethasone (drug), Pomalidomide (drug), Belantamab mafodotin (drug), Pegenzileukin (drug), SAR439459 (drug), Belumosudil (drug), Evorpacept (drug)
- Dates
- Started 2021-01-25; completion 2028-04-20
- Results posted
- Not yet
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $156,235 in research payments for this study in 2025 (8 payments).
Products named: Sarclisa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ajay K. Nooka, M.D., M.P.H.,F.A.C.P Medical Oncology · Atlanta, GA
- Erica L. Campagnaro, MD Hematology · Ann Arbor, MI
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Jens Hillengass, MD Medical Oncology · Buffalo, NY
- Francesca Cottini, MD Hematology · Columbus, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Health Research Inc Roswell PArk Division $71,123
- Emory University Hospital, GA $35,228
- The Ohio State University $33,284
- University of Michigan Health System, MI $16,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.